Therapeutic subgroup
R03 – MITTEL BEI OBSTRUKTIVEN ATEMWEGSERKRANKUNGEN
- Anatomical main group R: RESPIRATIONSTRAKT
22Decisions
40Patient groups
Added benefit by patient group
- Considerable3
- Minor7
- Non-quantifiable1
- Not proven28
- Lesser benefit1
Subgroups
Decisions, newest first
- 2026-10-01ExdensurDepemokimabNot proven
- 2026-10-01ExdensurDepemokimabNot proven: 2 of 2 patient groups
- 2026-09-03NucalaMepolizumabNot proven
- 2026-05-07TezspireTezepelumabNon-quantifiable
- 2025-05-15FasenraBenralizumabNot proven: 2 of 2 patient groups
- 2023-05-12TezspireTezepelumabNot proven: 2 of 2 patient groups
- 2022-05-19NucalaMepolizumabConsiderable
- 2022-05-19NucalaMepolizumabNot proven
- 2022-05-19NucalaMepolizumabNot proven
- 2021-02-04Enerzair BreezhalerIndacaterol/Glycopyrronium/MometasonNot proven
- 2019-05-02Trelegy ElliptaFluticasonfuroat/Umeclidinium/VilanterolNot proven
- 2019-03-22NucalaMepolizumabNot proven
- 2018-08-16Trelegy ElliptaFluticasonfuroat/Umeclidinium/VilanterolNot proven
- 2018-08-02FasenraBenralizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-07-06CinqaeroReslizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-07-21NucalaMepolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-07-21Incruse Ellipta (previously Incruse)UmeclidiniumNot proven: 2 of 2 patient groups
- 2016-04-07Bretaris GenuairAclidiniumbromidConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2016-02-04Spiolto Respimat Olodaterol/TiotropiumMinor: 1 of 2 patient groupsLesser benefit: 1 of 2 patient groups
- 2015-07-16Brimica GenuairFormoterol/AclidiniumbromidConsiderable: 1 of 4 patient groupsMinor: 1 of 4 patient groupsNot proven: 2 of 4 patient groups
- 2015-01-08Anoro ElliptaUmeclidinium/VilanterolNot proven: 2 of 2 patient groups
- 2014-05-08Ultibro BreezhalerIndacaterol/GlycopyrroniumMinor: 2 of 4 patient groupsNot proven: 2 of 4 patient groups
Data status: 2026-10-29